Novartis Gene Therapies - Company Profile

Powered by

All the sales intelligence you need on Novartis Gene Therapies in one solution.

$ $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Novartis Gene Therapies fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Novartis Gene Therapies.

Back to companies

Novartis Gene Therapies: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Novartis Gene Therapies, formerly AveXis Inc, is a biotechnology company. It operates as a subsidiary of Novartis AG. The company develops treatments for rare and potentially fatal neurological genetic diseases. The company’s product, Zolgensm is a proprietary gene therapy candidate for pediatric patients for the treatment of spinal muscular atrophy. It is also pursuing gene therapies for Rett syndrome (AVXS-201), and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene (AVXS-301). It works in collaboration with various academic institutes and research centers to advance its investigational product candidates. Novartis Gene Therapies is headquartered in Bannockburn, Illinois, the US.

 Gain a 360-degree view of Novartis Gene Therapies and make more informed decisions for your business Gain a 360-degree view of Novartis Gene Therapies and make more informed decisions for your business Learn more
Headquarters United States of America
Address Suite 200, 2275 Half Day Road, Bannockburn, Illinois, 60015
Website www.avexis.com
Telephone 1 847 5728280
Industry Pharmaceuticals and Healthcare
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Novartis Gene Therapies premium industry data and analytics

20+

Catalyst Calendar

Proactively evaluate Novartis Gene Therapies’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

7

Clinical Trials

Determine Novartis Gene Therapies go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

6

Pipeline Drugs

Identify which of Novartis Gene Therapies’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Novartis Gene Therapies’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products
Zolgensma
Pipeline:
AVXS-101 - Spinal Muscular Atrophy
XYZ
XYZ
XYZ
Understand Novartis Gene Therapies portfolio and identify potential areas for collaboration Understand Novartis Gene Therapies portfolio and identify potential areas for collaboration Learn more
Image for loader

Competitor Comparison

Key Parameters Novartis Gene Therapies Biogen Inc Ionis Pharmaceuticals Inc Travere Therapeutics Inc Paratek Pharmaceuticals Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Bannockburn Cambridge Carlsbad San Diego Boston
State/Province Illinois Massachusetts California California Massachusetts
No. of Employees - 7,500 1,402 497 268
Entity Type Private Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Executives
Name Position Board Since Age
Dave Lennon President Senior Management - -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Novartis Gene Therapies key executives to enhance your sales strategy Gain insight into Novartis Gene Therapies key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?